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Opinion statement
The prognosis and long-term survival for patients with metastatic esophagogastric
cancer (EGC) is poor. Historically, the mainstay of treatment has been combination
chemotherapy. More recently, a number of targeted therapies have been developed
and are being studied with the goal of improving response rate and survival in patients
with metastatic EGC. To date, the only targeted therapy which has been clinically
approved is trastuzumab which targets the HER2/Neu oncogene. However, only a small
group of patients with EGCs are HER2 ampliﬁed, and there are other important targets/
pathways which play a role in the development of these cancers that are currently
being studied. With the identiﬁcation of these other clinically relevant pathways, it is
anticipated that several other therapies will be approved in the future.
Introduction
Esophagogastric cancers (EGCs) are composed of
tumors of three distinct anatomic areas and two dis-
tinct histological variants. Primary esophageal cancer
includes both squamous cell and adenocarcinoma
(AC) while tumors of the esophagogastric junction
and the distal stomach are almost exclusively adeno-
carcinomas. Recent epidemiological trends have
suggested that the incidence of esophageal and
esophagogastric junction adenocarcinomas has been
increasing over the last three decades. In contrast, the
incidence of esophageal squamous cell carcinoma has
decreased in the United States, while the incidence of
gastric adenocarcinomas has decreased globally [1–5].
Despite continued research in the biology and treat-
ment of EGC, the prognosis and long-term survival
remains poor for most patients.
A study of a cancer registry in the United States
found that the incidence of esophageal AC rose from
1.8 per 100,000 in 1987–1991 to 2.5 per 100,000
from 1992 to 1996 [6]. The estimated new cases of
esophageal AC in the United States in 2009 were
16,470 [1]. This cancer has been noted to be more
common in men and in whites compared to blacks.
Possible risk factors include gastroesophageal (GE)
reﬂux disease, smoking, and obesity. In contrast, the
incidence of gastric AC has been declining both in the
United States and worldwide. Despite its decreased
incidence, this cancer remains one of the most com-
mon forms of cancer worldwide, accounting for nearly
10% of global malignancies [7, 8]. Possible risk factors
include diets high in nitrosamine compounds and
salt, obesity, smoking, prior gastric surgery, and
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squamous cell carcinoma varies widely by geographic
region, and is the most common in Asia, Africa, and
Iran. Risk factors include smoking, alcohol abuse,
diets high in nitrosamine compounds, preexisting
esophageal disease, and human papillomavirus
infection.
Patients with EGC may present in a wide variety of
clinical scenarios. Common presenting symptoms
include weight loss, dysphagia, epigastric or abdomi-
nal pain, early satiety, gastrointestinal bleeding, or
anemia. Symptoms of advanced disease include tra-
cheoesophageal ﬁstulas, involvement of the recurrent
laryngeal nerve, and gastrocolic ﬁstulas. Patients with
metastatic disease may present with liver enlargement
secondary to liver metastases or ascites due to perito-
neal deposits. Smaller lesions may be discovered
incidentally on endoscopy or radiographic imaging
done for other indications. The diagnosis is conﬁrmed
on tissue biopsy usually obtained by upper gastroin-
testinal endoscopy. Clinical staging often involves
endoscopic ultrasound to assess depth of invasion and
regional lymph node involvement, and/or CT and PET
scans to assess for distant disease.
Current treatment options for localized EGCs
include surgery alone, combined modality strategies
such as pre- or post-op chemotherapy with or without
radiation, and deﬁnitive chemoradiation. In the met-
astatic setting, chemotherapy is the mainstay of
treatment, but results in only modest improvements
in survival with considerable toxicity. Most recent
clinical trials have focused on the addition of targeted
therapies to a chemotherapy backbone.
The prognosis of both locally advanced and met-
astatic EGC is poor. For locally advanced disease,
surgery alone results in a 5-year survival of only
20–25% [9, 10]. Combined modality therapy increases
the 5-year survival to approximately 30–35% [11–13].
Median overall survival in the metastatic setting is usu-
ally about 8–10 months [14].
Given the poor overall survival in the metastatic
setting with standard chemotherapy, this article will
focus on newer, targeted therapy options which are
emerging for the treatment of metastatic EGC.
Targeted therapies
Anti-HER2 therapies
• HER2/Neu or ERBB2 is a member of the HER tyrosine kinase
receptor family. When a peptide ligand binds to the extracellular
domain of the HER2 receptor, homo- and heterodimerization of
the receptor occurs leading to autophosphorylation of the kinase,
and downstream growth signaling is activated. HER2 overexpres-
sion has been noted in many types of human cancers, most
prominently in some breast cancers, and more recently in a subset
of EGCs.
• HER2 overexpression has been variably noted in GE junction AC
(mean 22%; range 0–43%) [15, 16]. The wide range of expression
is due to receptor testing mechanisms based on immunohisto-
chemistry (IHC) or ﬂuorescence in situ hybridization (FISH), as
well as the variability in patients’ cancer staging. In gastric and GE
junction AC, some studies have shown a correlation between HER2
ampliﬁcation by FISH and increasing depth of invasion, lymph
node involvement, and distant organ metastasis, as well as overall
poor survival [17]. To date, there is minimal data that have
recorded comparisons between FISH and IHC in gastric cancers.
However, based on extrapolation from the breast cancer literature,
FISH is felt to be a more reliable and reproducible method for true
HER2 ampliﬁcation [18].
• Anti-HER2 therapies that have been evaluated in metastatic EGCs
are the monoclonal antibody (moAb), trastuzumab, and the oral
small molecule tyrosine kinase inhibitor, lapatinib.
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• Trastuzumab (Herceptin, Genentech) is a humanized IgG1 moAb
against the HER2 receptor. This drug likely exerts its effects through
severalmechanisms,includingpreventingdimerizationofthereceptor,
increasingreceptorendocytosis anddestruction,inhibitingsheddingof
the extracellular domain, and inducing antibody dependent cytotoxic-
ity [18]. It has been approved by the FDA for use as adjuvant therapy in
combination with chemotherapy in HER2-ampliﬁed breast cancer and
as monotherapy or combination therapy in metastatic breast cancer.
• AphaseIIstudyevaluating21patientswithadvancedgastriccancerand
HER2 overexpression, who received trastuzumab and cisplatin showed
anoverallresponserateof35%,andstablediseasein17%[19].Another
phaseIIstudyof16HER2positivepatientswithadvancedgastriccancer
treated with trastuzumab, cisplatin, 5-FU, and leucovorin found a
response rate of 55%, and a median overall survival of 8 months [20].
• Because of its success in the treatment of HER2-ampliﬁed breast cancer,
the phase III randomized ToGA trial evaluating trastuzumab in com-
bination with chemotherapy was launched. The trial examined the
addition of trastuzumab to a backbone of ﬂuoropyrimidine (either
capecitabine or 5-FU) and cisplatin chemotherapy for patients with
HER2 positive advanced gastric or GE junction cancer [21]. The study
enrolled patients with inoperable locally advanced, recurrent, or
metastatic AC of the stomach or GE junction that were HER2 positive
by FISH or 3+ positive by IHC. Of tumors from 3807 patients, 22.1%
were found to be HER2 positive. Five-hundred ninety four patients
were randomized, and 584 of these underwent treatment, with 20
among them having had locally advanced disease, and 564 metastatic
disease. There was a statistically signiﬁcant increase in overall response
rate (47.3% vs 34.5%), median progression free survival (6.7 vs
5.5 months) and median overall survival (13.8 vs 11.1 months) in
favor of the trastuzumab containing arm. There was no unexpected
toxicity in the trastuzumab arm, but as expected there was an increased
incidence of asymptomatic decrease in the left ventricular ejection
fraction [22•]. Furthermore, in a recent analysis, quality of life was not
compromised at all in the trastuzumab-treated group making this a
clinically signiﬁcant improvement [23]. The ToGA trial is the ﬁrst
positive phase III study of targeted therapy for the treatment of EGCs,
and validated the role of trastuzumab chemotherapy combination as a
new standard treatment for patients with HER2 positive EGCs.
• In the ToGA trial, trastuzumab was dosed at 8 mg/kg on Day 1 of
cycle 1, followed by 6 mg/kg every three weeks until disease pro-
gression or unacceptable toxicity. The drug may enhance cardiotoxic
effects of anthracyclines, neutropenic effects of immunosuppressants,
and may increase the serum concentration of paclitaxel when given in
combination. Typical side effects include cardiomyopathy, nausea,
weakness, and infusion reactions.
Lapatinib
• Lapatinib (Tykerb, GlaxoSmithKline) is an oral tyrosine kinase
inhibitor (TKI) which has activity against both EGFR and HER2
kinases. The FDA has approved lapatinib in combination with
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progression on trastuzumab, an anthracycline, and a taxane.
• The Southwest Oncology Group (SWOG) performed a phase II study
evaluating lapatinib as ﬁrst-line therapy in 47 patients with advanced
gastric cancer [24]. Only three patients (7%) had a documented partial
response, median time-to-treatment failure was 2 months, and median
overallsurvivalwas5 months.Thelowoverallsurvivalrateinthisstudy
would suggest that lapatinib as a single agent will not prove to provide
adequatediseasecontrol.AsecondphaseIIstudyevaluatedlapatinibin
25patientswho wereEGFRpositivebyIHCorHER2positivebyIHCor
FISH whose disease had progressed through multiple prior therapies
[25]. The overall response rate was 0%, but two patients had stable
disease for 5 and 9 months, respectively. A third study evaluated 16
patients with HER2 ampliﬁed GE junction tumors [26]. This study was
closed early due to lack of response and slow accrual. One patient
achieved a durable complete remission (maintained at week 60), and
another patient had stable disease at week 36.
• Extrapolating from its success rate in breast cancer, two phase III
studies are currently evaluating the role of lapatinib in combination
with chemotherapy for the treatment of advanced EGC. The LOGIC
trial is evaluating the combination of capecitabine/oxaliplatin ±
lapatinib as ﬁrst-line therapy for HER2 overexpressing EGCs. The
TYTAN trial is an Asian study evaluating lapatinib in combination
with paclitaxel as second-line therapy in gastric cancer. Both these
studies are still in progress, and ﬁnal results are pending.
• Lapatinib is being dosed at 1250 mg/day in these trials. Lapatinib can
enhance the QTc prolonging effects of many drugs, and increase or
decrease the metabolism of CYP3A4 substrates. Side effects include
but are not limited to fatigue, rash, diarrhea, cytopenias, and elevated
transaminases and bilirubin.
• Trials of anti-HER2 therapies that have been reported are shown in
Table 1.
Anti-EGFR therapy
• EGFR or erbB1 is another member of the erbB tyrosine kinase family.
Binding of ligand to the receptor causes dimerization either with itself
or another member of the erbB family. Dimerization leads to tyrosine
Table 1. Summary of trials of anti-HER2/Neu-targeted therapies in metastatic EGCs
Agents Trial
design
Stage Histology No. of
Pts
ORR OS Author
5-FU or capecitabine
+ Cis vs
Trastuzumab
+ 5-FU or
capecitabine + Cis
Randomized
Phase 3
Locally advanced: 10 Gastric AC: 242 290 34.5% 11.1 mos Bang et al.
Locally advanced: 10 Gastric AC: 236 294 47.3% 13.8 mos
Metastatic: 280 GE junction AC: 48
Metastatic: 284 GE junction AC: 58
Lapatinib Phase 2 Metastatic Gastric AC 47 7% 5 mos Iqbal et al.
Lapatinib Phase 2 Metastatic Esophageal AC: 12 25 0% NS Hecht et al.
Her-2 amplified GE junction AC: 13
Lapatinib Phase 2 Metastatic GE junction AC 16 6% NS Galsky et al.
Her-2 amplified
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downstream signals regulate the cell cycle, apoptosis, cell prolifera-
tion, and angiogenesis. EGFR is normally expressed in many tissues
including the skin, gut, and kidney, and has been shown to be over-
expressed in certain cancers. Overexpression by IHC or FISH in EGCs
has been seen in 30–90% of tumors, and correlates with increased
invasion, poorly differentiated histology, and worse prognosis. To
date, there has been no correlation demonstrated between EGFR by
IHC and response to anti-EGFR therapies. Finally, in contrast to
adenocarcinoma of the lung, mutations in the EGFR kinase domain
are exceedingly rare in gastric and esophageal cancers [27–30].
• kras is an oncogene downstream of EGFR, which is involved in signal
transduction. Colon cancer patients with kras mutations do not seem
to derive beneﬁt from the anti-EGFR moAbs, cetuximab, or pani-
tumumab. Little is known about the incidence of kras mutations or
the signiﬁcance of these mutations for treatment in patients with
EGCs. In one study, none of the 38 patients was found to have
mutated K-ras, and in another study two of 23 patients had a muta-
tion suggesting that mutations in kras are exceedingly rare [31, 32].
• Anti-EGFR therapies which have been evaluated in metastatic EGCs
include the moAbs (cetuximab, panitumumab, and matuzumab) and
oral, small molecule TKIs (erlotinib and geﬁtinib). It should be noted
that unlike in the case with HER2 inhibitors, no EGFR-related criteria
were required in selecting patients for the large majority of these trials.
Cetuximab
• Cetuximab (Erbitux, Imclone Systems) is a partially humanized
murine IgG1 moAb which binds EGFR and blocks ligand binding to
the receptor, stimulates EGFR receptor endocytosis, and initiates im-
mune-mediated cytotoxicity [33]. The FDA has approved cetuximab
for use in irinotecan refractory colorectal cancer, and for use in
combination with radiotherapy for treatment of locally advanced
head and neck squamous cell carcinoma.
• In the metastatic setting, multiple trials have evaluated cetuximab with
various chemotherapy regimens, including FOLFIRI (biweekly bolus
5-FU, leucovorin, irinotecan, and infusional 5-FU), FUFIRI (weekly
irinotecan/infusional 5-FU/leucovorin), FOLFOX, FUFOX (weekly
oxaliplatin/leucovorin/infusional 5-FU), 5FU/cisplatin, continuous
infusion 5-FU/leucovorin/cisplatin, capecitabine/cisplatin, cisplatin/
docetaxel, and oxaliplatin/irinotecan. The FOLFIRI trial was the only
one which required tumors to be EGFR positive by IHC. The overall
response rates in these trials were 40–69% and median overall survival
was 9.5–17 months [31, 32, 34–41].
• The Cancer and Leukemia Group B (CALGB) recently reported results
of a randomized phase II trial combining cetuximab with either ECF
(epirubicin, cisplatin, and infusional 5-FU), cisplatin/irinotecan, or
FOLFOX for the treatment of metastatic esophageal or GE junction
cancers [42••]. Cetuximab plus ECF or FOLFOX had response rates
greater than 40%. As the purpose of the trial was to determine the best
chemotherapy backbone for further study, none of the arms contained
a true control. Biomarker correlatives including EGFR and kras are
currently ongoing in this trial. Cetuximab is currently being tested in
an ongoing randomized phase III trial in Europe.
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beyond. Data from these studies suggest that this is not a promising
approach. In a study done by SWOG in 55 patients with advanced
esophageal and GE junction AC receiving cetuximab as second-line
treatment, one patient had a conﬁrmed partial response and median
survival was 1.8 months [43–46].
• In these trials, cetuximab is usually dosed at 400 mg/m
2 on week 1
followed by 250 mg/m
2 weekly. Toxicities seen in the various studies
include neutropenia, diarrhea, skin toxicity, and rare cases of ana-
phylaxis.
Panitumumab
• Panitumumab (Vectibix, Amgen) is a fully humanized IgG2 moAb
against EGFR which has been approved by the FDA for treatment of
chemorefractory EGFR-positive colorectal cancer. This drug is cur-
rently being evaluated for treatment of metastatic EGCs. In a phase I
study which included three patients with EGC, one patient had stable
disease for 7 months [47]. The REAL3 trial is currently being done in
the UK to evaluate EOX (epirubicin, oxaliplatin, and capecita-
bine) ± panitumumab but at the planned doses, the trial has
encountered signiﬁcant toxicities including an 80% rate of grade 3
diarrhea [48]. As a consequence, the study was temporarily halted
while formal dose-ﬁnding studies were conducted. The trial has now
resumed with lower doses of both capecitabine and oxaliplatin with
the standard dosing of panitumumab at 6 mg/kg every 2 weeks. The
most common side effect is skin toxicity, diarrhea and electrolyte
abnormalities (hypokalemia, hypomagnesiumia).
Matuzumab
• Matuzumab, a humanized monoclonal Ab against EGFR, has been
evaluated in Phase I studies for treatment of metastatic esophagoga-
stric cancer. This drug has not yet received FDA approval. In one study,
1 of 2 patients with esophageal SCC had a durable 6-month partial
response [49]. In another study, the drug was combined with ECX
(epirubicin, cisplatin, and capecitabine) for ﬁrst-line treatment of
EGFR-positive gastric and GE junction AC [50]. Of the 21 patients,
overall response rate in 20 patients was 65% and median time-to-
progression was 5.2 months.
Erlotinib
• Erlotinib (Tarceva, Genentech) is a small molecule anti-EGFR tyrosine
kinase inhibitor. It inhibits ATP binding within the tyrosine kinase
domain leading to inhibition of autophosphorylation and signal
transduction. The FDA has approved erlotinib for use as second or
third-line treatment for non-small cell lung cancer, maintenance
therapy for non small cell lung cancer, and as ﬁrst-line treatment in
combination with gemcitabine for pancreatic cancer.
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tory-advanced gastric and GE junction AC [51••]. Interestingly, in this
trial in the patients with gastric primaries, there were no responses.
However, in the 44 patients with GE junction tumors, the overall
response rate was 9% and median time-to-failure was 2 months.
Based on these results, we recently completed a trial investigating the
addition of erlotinib to modiﬁed FOLFOX6 chemotherapy restricting
the trial to gastroesophagus junction tumors only [52]. In this phase II
trial of 38 patients, the response rate was 50% with an overall survival
of 11 months.
• Erlotinib is dosed at 150 mg daily. Antacids can decrease serum
concentration of erlotinib, and erlotinib may increase or decrease
metabolism of CYP3A4 substrates. Possible side effects include rash,
diarrhea, nausea, and decreased appetite.
Gefitinib
• Geﬁtinib (Iressa, AstraZeneca Pharmaceuticals) is also a small mole-
cule TKI. It has been used for the treatment of locally advanced or
metastatic non-small cell lung cancer after failure of platinum-based
and docetaxel therapies. Studies using geﬁtinib as a single agent for
treatment of EGC have also only produced modest results. Geﬁtinib
was studied in a phase II evaluation as second-line treatment for 28
patients [32]. One patient had a 3-month partial response, and 10
patients had stable disease. Another study evaluated geﬁtinib as either
ﬁrst or second-line therapy for esophageal and GE junction adeno-
carcinoma [53]. The overall response rate was 11%, but overall sur-
vival was 4.5 months.
• Geﬁtinib is dosed at 500 mg daily. Geﬁtinib may increase or decrease
the metabolism of CYP3A4 substrates, and can enhance the antico-
agulant effect of warfarin. Possible side effects include rash, diarrhea,
and nausea.
• Based on the number of trials that have been done to date, it seems
likely that to achieve improved outcomes, these agents will also need
to be added to a chemotherapy backbone.
• Trials of anti-EGFR therapies that have been reported are shown in
Table 2.
Anti-vascular endothelial growth factor
• Vascular endothelial growth factor (VEGF) is a regulator of angio-
genesis. It plays a role in endothelial cell mitogenesis and migration,
remodeling of the extracellular matrix, increased vascular permeabil-
ity, and maintenance of survival for newly formed blood vessels [54].
VEGF is overexpressed in 30–60% of patients with esophageal cancer,
and some studies have shown a correlation between VEGF overex-
pression, advanced stage, and poor survival [55–59].
• Anti-VEGF therapies which have been studied include the moAb,
bevacizumab, as well as the multi-target TKIs, sunitinib, sorafenib,
and telatinib.
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Targeted Therapies for EGC Reddy and Wainberg 53Bevacizumab
• Bevacizumab (Avastin, Genentech) is a humanized IgG1 moAb
against VEGF. The FDA has approved bevacizumab for the treatment
of metastatic colon cancer, metastatic nonsquamous non-small cell
lung cancer, progressive glioblastoma, and metastatic renal cell car-
cinoma.
• Several phase II studies of bevacizumab for treatment of metastatic
EGC showed encouraging results. One study combined bevacizumab
with cisplatin/irinotecan for 47 patients, and showed an overall sur-
vival of 12.3 months [60]. Another study combined bevacizumab with
docetaxel/cisplatin/irinotecan in 44 patients, and showed overall re-
sponse rate of 67% and overall survival of 16.2 months [61]. Other
evaluations in combination with various chemotherapy regimens have
shown similar overall response rates [62, 63]. Bevacizumab has also
been evaluated in the second-line setting in combination with doce-
taxel with an overall response rate of 24% in 17 evaluable patients [64].
Given the promising phase II data, the phase III AVAGAST study was
launched to evaluate ﬁrst-line ﬂuoropyrimidine (5-FU or capecitabine)
and cisplatin plus bevacizumab or placebo in patients with advanced
gastric cancer [65••]. There were 774 patients enrolled in this trial, and
approximately 95% had metastatic disease. Despite some advantages,
there was no statistically signiﬁcant difference in median overall sur-
vival (10.1 months with chemotherapy vs 12.1 months with chemo-
therapy plus bevacizumab). Interestingly, there was a statistical
advantage in the bevacizumab groups for both response rate (29.5%
for placebo vs 38% for bev) and PFS (5.3 months for placebo vs
6.7 months for bev). Furthermore, in a subset analysis of geographical
regions, patients in the Americas did have an advantage in overall
survival (6.8 months for placebo vs 11.5 months for bev). While the
Americas cohort was small (approximately 150 patients), these results
are provocative and suggest that the geographical heterogeneity of
these disease may also reﬂect differences in responses to targeted
agents. Additional studies with bevacizumab in EGC that are currently
ongoing may provide additional insight into the appropriate patients
for this agent (Table 3).
• Bevacizumab is dosed at 7.5 mg/kg every three weeks. Possible side
effects include hypertension, thromboembolic events, and gastroin-
testinal perforation or bleeding.
Sunitinib
• Sunitinib (Sutent, Pﬁzer) is an oral multi-target TKI that has activity
against the VEGF receptor. The FDA has approved sunitinib for ﬁrst-
line therapy for advanced renal cell carcinoma and for imatinib resis-
tant gastrointestinal stromal tumors. In a phase II study, 78 patients
received sunitinib as second-line treatment for advanced EGC [66].
Two patients had partial response, and 25 had stable disease for at least
6 weeks. Median overall survival was 6.8 months. In this study, suni-
tinib was dosed at 50 mg/day with four weeks on, two weeks off.
There are no major contraindications to administration of this drug.
Sunitinib has multiple drug interactions including enhancing the QTc
prolonging the effects of other agents, and increasing or decreasing the
metabolism of CYP3A4 substrates. Possible toxicities include hyper-
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Targeted Therapies for EGC Reddy and Wainberg 55tension, cytopenias, transaminitis or elevated alkaline phosphatase
and bilirubin, and hand–foot syndrome.
Sorafenib
• Sorafenib (Nexavar, Bayer), like sunitinib, is also a multi-targeted TKI
with activity against the VEGF receptor. The FDA has approved
sorafenib for treatment of advanced renal cell carcinoma and hepa-
tocellular carcinoma. The Eastern Cooperative Oncology Group per-
formed a phase II study of sorafenib with docetaxel/cisplatin for ﬁrst-
line treatment of 53 patients with metastatic or unresectable gastric or
GE junction AC, with overall response rate of 38.6% and median
overall survival 14.9 months [67]. Sorafenib is dosed at 400 mg twice
daily. Sorafenib may increase serum concentration of doxorubicin and
irinotecan, and may decrease serum concentration of ﬂuorouracil.
Side effects are similar to those of sunitinib.
Telatinib
• Finally, telatinib is a small molecule oral TKI which selectively targets
the VEGF and platelet-derived growth factor (PDGF) receptors. The
drug has not been FDA approved. Preliminary results from a phase II
study was recently reported evaluating telatinib in combination with
capecitabine and cisplatin as ﬁrst-line treatment in patients with
advanced cancer of the stomach or GE junction [68].
mTOR inhibitors
• The mTOR pathway is a downstream component of the phosphati-
dylinositol 3-kinase/Akt kinase signaling pathway. This pathway reg-
ulates cell growth and metabolism by acting as a sensor for nutrients
and growth factors. In gastric cancer, upregulation of this pathway has
been linked to poor prognosis [69].
Everolimus
• Everolimus (Aﬁnitor, Novartis) is an oral mTOR inhibitor which is
approved by the FDA for treatment of sunitinib or sorafenib resistant
renal cell carcinoma. A Japanese phase II study evaluated using ever-
olimus in 53 treatment-refractory gastric cancer patients [70••].
Although there were no responses, a decrease in tumor size from
baseline was observed in 45% of patients, and median overall survival
was 10.1 months. The GRANITE-1 study is a phase III study currently
evaluating everolimus plus supportive care vs placebo plus supportive
care for treatment of advanced gastric cancer after progression on prior
chemotherapy. Results of this study are pending. Everolimus is dosed
at 10 mg daily. Everolimus has multiple drug interactions including
interactions with CYP3A4 inducers and inhibitors. Side effects include
stomatitis, edema, hypertension, rash, fatigue, cytopenias, rise in
creatinine, and cough.
56 Esophageal and Gastric CancerOther targets
• Other targets that have been evaluated in a small number of clinical
studies include c-MET, matrix metalloproteinases (MMPs), and pro-
tein kinase C.
• C-MET is the receptor for hepatocyte growth factor. Ligand binding to
the receptor stimulates tyrosine kinase phosphorylation, further signal
cascade, and cell proliferation. The c-MET protein has been found to
be overexpressed in some EGCs and correlates with a poor prognosis.
A phase II study evaluated two dosing schedules for GSK1363089
(foretonib), a dual MET/VEGFR2 inhibitor in patients with metastatic
gastric cancer [71]. The study found that c-MET ampliﬁcation in
metastatic gastric cancer is rarer than anticipated (3/43 patients).
However, the lack of a well-validated method to assess c-MET
expression/mutation/ampliﬁcation makes any conclusive interpreta-
tions premature. The best response was stable disease noted in 15%
and 21% of the two different cohorts. Unfortunately, ampliﬁcation of
the MET oncogene was not associated with a higher response rate.
Other clinical trials of various c-MET inhibitors (TKI’s and monoclo-
nal antibodies) are ongoing.
• MMPs are proteolytic enzymes that break down components of the
extracellular matrix and play a role in cell growth and repair. Ma-
rimastat, an MMP inhibitor was evaluated in a phase III study vs
placebo in 369 patients with metastatic or inoperable GE junction AC
[72]. At the end of 2 years, there was a small but signiﬁcant difference
in overall survival (160 vs 138 days) and 2-year survival (9% vs 3%)
favoring the marimastat group (P = 0.02). However, this class of drugs
is no longer being tested in clinical trials in EGC.
• Finally, protein kinase C mediates anti-apoptotic signals. Bryostatin-1
is an inhibitor of protein kinase C. Two different phase II studies have
evaluated bryostatin-1 in combination with paclitaxel for treatment of
EGC [73, 74]. Both studies suggested that this may be an active
combination, but the drug was not further evaluated because of sig-
niﬁcant grade 3/4 myalgias which occurred in about half the patients.
Nonetheless, other PKC inhibitors are under investigation in a variety
of malignancies including gastric cancers.
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